Alabama Clinical Trials

A listing of Alabama clinical trials actively recruiting patient volunteers.

Filter by Condition
1172 trials found

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

NCT04595513

This trial will use a two stage, phase I/II clinical trial design. The first stage will employ an open-label clinical trial design to verify dosing for TAVT-18 (sirolimus) powder for oral solution in TSC infants (N=5). Results will then be carried forward to inform appropriate initial dosing, dosing frequency, and dosing adjustments for the second stage, a randomized, double-blind, placebo-controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seiz ...

Conditions: Tuberous Sclerosis Complex, Epilepsy
Phase: Phase 1/2

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

NCT04587323

To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.

Conditions: COVID-19 Disease

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).

Conditions: Triple-Negative Breast Cancer

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949

This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as repeating that duration for a total of 84 days/12 weeks treatment.

Conditions: Smoking Cessation

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980

The long-term goal is to study the safety and effectiveness of hormonal contraception for women with cystic fibrosis (CF) and contribute to national guidelines that the Cystic Fibrosis Foundation and the Centers for Disease Control and Prevention (CDC) provide to clinicians. The study objectives are to determine whether hormonal contraceptive methods improve overall pulmonary health, worsen CF-related disease or CF liver disease, or are effective against unwanted pregnancy with concomitant CF tr ...

Conditions: Cystic Fibrosis, Contraception

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115

The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined dosing interval ([AUC0-τ] either every 3 weeks [AUC0-21 days] or every 4 weeks [AUC0-28 days]) and maximum concentration in a dosing interval (Cmax) in participants diagnosed with primary humoral immunodeficiency (PI) currently receiving chronic IVIG replacement treatment.

Conditions: Primary Immunodeficiency

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068

This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection

Conditions: Sexually Transmitted Diseases, Gonorrhea, Chlamydia

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060

This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.

Conditions: Covid19
Phase: Phase 2/3

COVID-19 Study of Safety and Tolerability of Alvelestat

NCT04539795

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18 years) with COVID-19 respiratory disease.

Conditions: Covid19
Phase: Phase 1/2

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794

This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.

Conditions: Chronic Spontaneous Urticaria

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208

The primary objectives of the study are: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group. To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection. The secondary objectives of the study are: To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study ...

Conditions: COVID-19 (Healthy Volunteers)
Phase: Phase 1/2

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

NCT04529096

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.

Conditions: Chronic Low-back Pain